It is easy to forget that within the lifetime of many of the readers of the Scottish Medical Journal there was no life-sustaining treatment for end-stage chronic renal failure (ESCRF). The ability to keep patients with ESCRF alive with renal replacement therapies (RRT) (kidney transplantation, haemodialysis and peritoneal dialysis) was one of the great medical advances of the 20th century. A total of 512 patients started RRT in Scotland in 2013 and at the end of 2013 there were 4600 prevalent patients on RRT in Scotland. Fifty-four per cent of these prevalent RRT patients had a functioning kidney transplant. 1 The first renal transplant in United Kingdom was performed between identical twins in Edinburgh by Sir Michael Woodruff in 1960, six years after the first ever successful renal transplant, also between identical twins, by Joseph Murray in the USA. Since then a further 5879 kidney transplants have been performed in 4931 patients resident in Scotland. Early progress was hampered by an inability to detect transplants at high risk of hyperacute rejection and by limited availability of effective immunosuppression. By the 1980s, renal transplantation was becoming widely available and was provided in four centres in Scotland (Aberdeen, Dundee, Edinburgh and Glasgow). Renal transplantation is now centralised in Edinburgh and Glasgow with each serving approximately half of the Scottish adult population, and all paediatric renal transplants being performed in Glasgow. The introduction of cyclosporine in the early to mid 1980s led to a substantial reduction in acute rejection and one year transplant survival approaching 90%. Improving success inevitably led to increased demand.
For patients deemed fit enough, kidney transplant offers advantages over dialysis, with fewer social and dietary restrictions, better general well-being, resumption of normal growth in children and restoration of fertility in women. Observational studies consistently demonstrate a survival advantage compared with staying on the waiting list including in high-risk subgroups. 2 These studies suggest the average patient will live 10-15 years longer with a renal transplant than on dialysis. Transplantation is also much less costly than dialysis. There is a clinical price to pay in that the patient needs to undergo major surgery and needs to take immunosuppressive medicines, rendering them more susceptible to infection and malignancy, meaning that approximately only a third of patients with ESCRF are deemed fit enough for transplant.
In this issue of the SMJ, Murray et al. 3 provide an interesting insight into the evolution of eligibility for deceased donor renal transplantation by comparing the transplant waiting lists for renal transplant in the West of Scotland in 1988 and 2011. The 2011 list had many more patients and these patients were older on average. Further analysis would also have demonstrated more co-morbidity in the 2011 cohort. Data for the whole of the UK also demonstrated increasing recipient and donor age and donor co-morbidity in recent years as the acceptance criteria for both donors and recipients relaxed. Despite this the short-and longterm outcomes for renal transplantation have steadily improved in the last 20 years with 1 and 5 year transplant survival approaching 95% and 85%, respectively. 4 A large number of factors are responsible for these improvements. Technological advances mean improved ability to match human leucocyte antigens (HLA) in donors and recipients at the molecular level and detect pre-formed circulating donor-specific anti-HLA antibodies before transplant. Donor organ allocation schemes have been refined and transplant surgery procedures optimised to minimise cold ischaemia times before implantation. Immunosuppressive regimens have been refined to reduce rates of acute rejection from approximately 35% in the first year after transplant 20 years ago to approximately 10-15% currently. For patients intolerant of particular immunosuppressant medicines, alternatives are now available. The ability to prevent, identify and treat opportunistic infection such as cytomegalovirus and pneumocystis pneumonia has improved substantially. Modern chronic kidney disease management includes much earlier planning for transplant meaning that an increasing proportion of patients have transplant as their first RRT modality, a strategy known to be associated with better long-term outcome.
This improvement in outcome means that the risk/ benefit for marginal candidates has become more favourable, meaning that demand continues to increase. Recent attempts to increase renal transplantation in the UK have been highly successful, so much so that the last three years have seen the first ever small reductions in the waiting list for renal transplant. 4 In the last decade in Scotland, the number of renal transplants has risen from 124 in 2004 to 269 in 2013. 1 This increase has been possible because of the introduction of donation after circulatory death as well as donation after brain death, and by an increase in living kidney donation. The increase in living donor transplantation has included paired pooled donation (the sharing of transplants between immunologically incompatible living donor pairs), non-directed living donation (where a person donates but does not stipulate who should receive the donated kidney), blood group incompatible donation and HLA antibody incompatible donation, all made possible by technological advances or changes in legislation. The infrastructure and teamwork required in identifying a potential donor, mobilising a retrieval team, obtaining informed consent sensitively from a deceased donor family, identifying the best recipient, transporting the retrieved organ and implanting the organ in the shortest possible time cannot be underestimated.
Many challenges remain in kidney transplantation. Balancing equity of access and utility of a scarce resource continues to stimulate vigorous ethical debate. Defining acceptable criteria for deceased donation in a short period of time without 'wasting' potentially suitable organs always carries a risk as highlighted by the recent cases of transfer of fatal infection to two recipients from one donor in Wales (http:// www.bbc.co.uk/news/uk-wales-30050902; accessed 15 December 2014). Defining 'fitness' for transplant remains controversial and probably condemns too many patients to life-long dialysis. Novel strategies to protect the retrieved kidney from ischaemic injury before implantation, such as ex-vivo normothermic perfusion, are in their infancy. The tools to detect adequate suppression of the donor specific immune reaction remain crude and probably result in many patients being far more immunosuppressed than they need to be. Each new advance in understanding the alloimmune reaction emphasises how far we are from the goal of achieving true tolerance whereby an intervention can block the alloimmune reaction permanently whilst also preserving immune competence against infection and oncogenesis. Clinical renal xenotransplantation has not progressed significantly from early promise and the tantalising prospect of growing functioning kidney units in vitro for implantation remains a distant aspiration.
The knowledge gained from renal transplantation has paved the way for other solid organ transplants, and the science of the alloimmune reaction has contributed greatly to knowledge of clinical immunology and informed therapeutics in a wide range of diseases. The high success rate of transplantation in the modern era makes it more difficult to test new interventions in clinical trials. The medical community is indebted to the courage of the pioneering transplant patients and clinicians. That same courage is needed to tackle the many challenges that remain. It will be interesting to see how the transplant waiting list of 2034 compares to that of 2011.
